Developing advanced technology to analyze antibodies for SARS-CoV-2
Official title: New Technology for High-Resolution Antibody Profiling for SARS-CoV-2
Funded at Ambergen, INC · NIH-10686794 · Data updated 2026-11-12
This study is working on a new way to closely examine how your immune system responds to COVID-19, including how vaccines help and what happens with long-COVID, so that doctors can provide better, more personalized care for patients like you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ambergen, INC NIH-funded |
| Lab location | 1 site (Watertown, United States) |
| Project start | August 19, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $978,625 |
| NIH project number | 5R44AI165129-02 |
| Project ID | NIH-10686794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have been infected with SARS-CoV-2, those experiencing long-COVID symptoms, and vaccinated individuals.
✕Less likely to help
Patients who have not been infected with SARS-CoV-2 or have not received a COVID-19 vaccine may not benefit from this research.
What this research studies
This research focuses on creating a new technology for high-resolution antibody profiling specifically for the SARS-CoV-2 virus. By utilizing a mass spectrometric bead-array method, the project aims to enhance the understanding of the immune response to COVID-19, including the effects of vaccination and the development of long-COVID. The approach involves detailed analysis of antibodies to identify their structure and function, which could lead to improved diagnostics and treatments for COVID-19. Patients may benefit from more personalized and effective healthcare solutions based on their immune responses.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostics and treatments for COVID-19 and its long-term effects.
How similar studies have gone: Other research has shown promise in antibody profiling technologies, indicating potential for success with this novel approach.
Where this research is happening
-
Ambergen, INC
Watertown, United States Active
Researchers
- Principal investigator: Lim, Mark — Ambergen, INC
- Study coordinator: Lim, Mark
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.